



ABN 53 075 582 740

**ASX Announcement**  
**10 April 2015**

---

## **BNC105 BIOMARKER DATA TO BE PRESENTED AT ASIAN ONCOLOGY CONFERENCE**

**Bionomics Limited (ASX: BNO, OTCQX: BNOEF)** today announced that it will present a poster with new data on the DisruptOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7<sup>th</sup> Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

The poster will be presented by Dr. Jeremy Simpson, Vice President, Clinical Development at Bionomics, and is entitled, *A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC): Results of the randomized phase II DisruptOR-1 trial*. The Poster Walk session is during the Welcome Reception on Friday, April 10th, 2015 at 5:45 p.m. CST in the Mandarin Hall of the Oriental Riverside Hotel and Convention Centre .

The data identify ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression free survival (PFS) in patients. Eighty nine percent of patients expressing higher plasma levels of ferritin and lower plasma levels of IL-8 at baseline were disease progression-free at six months. The data show that biomarker-based patient selection has the potential to optimise clinical outcomes in the treatment of renal cancer. There are 6.3 new cases of renal cancer and 1.7 deaths per 100,000 people in Asia each year.

BNC105 is a novel compound being developed as a vascular disrupting agent (VDA) for the treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. This approach has a number of advantages over classical chemotherapy, including stronger impact on tumour cell death, applicability to a wider variety of cancers, and lowered risk of the emergence of therapy-resistant tumour cells.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

**Bionomics Limited**  
Dr Deborah Rathjen  
CEO & Managing Director  
+61 (0)8 8354 6101  
0418 160 425  
[drathjen@bionomics.com.au](mailto:drathjen@bionomics.com.au)

**Monsoon Communications**  
Rudi Michelson  
+61 (0)3 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**Stern IR**  
Beth DelGiaccio  
+1 (212) 362 1200  
[beth@sternir.com](mailto:beth@sternir.com)

### **About Bionomics Limited**

Bionomics (ASX: BNO) is a biopharmaceutical company that discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform that incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics' partners include Merck & Co.

[www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors' products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.